Pediatric acute lymphoblastic leukemia relapse and prognosis: key predictors and therapeutic implications.

ABSTRACT:

Background

Pediatric acute lymphoblastic leukemia (ALL), the most common childhood malignancy, achieves >95% 5-year survival with risk-adapted therapies. Nonetheless, 10%-15% of patients experience relapse, with post-relapse survival <50%. Challenges remain in optimizing minimal residual disease (MRD)-guided strategies and salvage therapies in ALL.

Aims

This study aimed to identify relapse predictors and assess post-relapse outcomes among 436 pediatric ALL patients treated according to the CCCG-ALL-2015 protocol.

Results

Of the 436 enrolled patients (median age: 3.9 years; 92.4% B-ALL), sixty-four patients (14.7%) relapsed, predominantly with isolated bone marrow involvement (71.9%). Independent predictors included thrombocytopenia at diagnosis (OR = 2.09, P = 

SUBMITTER: Chen X 

PROVIDER: S-EPMC12756419 | biostudies-literature | 2025

REPOSITORIES: biostudies-literature